Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

This month’s Research Spotlight highlights significant advancements in pancreatic cancer research and patient support.

There are two main types of pancreatic cancers—those that start in the exocrine gland and those that start in the endocrine cells. Pancreatic cancer is a rare, but deadly disease. Treatment options ...

Why This Matters Pancreatic cancer is one of the most difficult cancers to treat, with limited treatment options and a low survival rate. One reason for this is that pancreatic tumors don’t ...

Pancreatic cancer is one of the most devastating cancers because it usually doesn’t exhibit symptoms until it’s too far advanced for effective treatment. As Pancreatic Cancer Action Network ex ...

A New Way to Identify High-Risk Patients Currently, doctors use different guidelines worldwide to classify pancreatic ... start treatment before the cancer spreads. Another major benefit of ...

The study, published in Science Advances, identifies the molecule Neuropeptide Y (NPY) as a key driver of pancreatic cancer metastasis – the process by which cancer spreads to other organs.

the treatment may not necessarily stop working," Vonderheide explained. The research team found that not only was RAS(ON) multi-selective inhibition effective in preclinical pancreatic cancer ...

Blood tests that detect early cancer are coming to market. Could they lead to earlier diagnosis and treatment?

As few as one in ten people survive pancreatic cancer five years after their diagnosis — making it the most difficult cancer to survive. The survival rate five years after diagnosis is 6-14%, but ...